Metropolis Health shares jumped more than 3% in morning trade after the company announced its solid Q3 results. As of 10:09 AM, the shares were trading 2.85% higher at Rs 1,787.45.
The company posted a 15.4% year-on-year (YoY) growth in net profit, reaching ₹31.4 crore for the quarter ending December 31, 2024, compared to ₹27.2 crore in Q3 FY24.
Revenue from operations grew 11% YoY to ₹322.8 crore, up from ₹291 crore in the same period last year, driven by higher diagnostic test volumes and expanding market presence.
The company’s EBITDA increased 11.2% to ₹72 crore in Q3 FY25, compared to ₹64.8 crore in the previous year. However, the EBITDA margin remained steady at 22.3%, indicating stable operational efficiency. EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) is a key profitability metric.
Metropolis Healthcare’s strong quarterly performance reflects growing demand in the diagnostic sector, supported by expanding healthcare infrastructure and preventive testing trends.
Metropolis Health shares opened at ₹1,755.00, reaching a high of ₹1,811.00 and a low of ₹1,755.00. The stock remains well below its 52-week high of ₹2,318.30 but above its 52-week low of ₹1,551.05.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
